Genelux Corporation (NASDAQ: GNLX)
$2.60
-0.0200 ( -0.76% ) 91.0K
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Market Data
Open
$2.60
Previous close
$2.62
Volume
91.0K
Market cap
$90.00M
Day range
$2.51 - $2.76
52 week range
$1.71 - $32.86
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 08, 2024 |
4 | Insider transactions | 1 | Jul 08, 2024 |
4 | Insider transactions | 1 | Jul 08, 2024 |
4 | Insider transactions | 1 | Jul 08, 2024 |
4 | Insider transactions | 1 | Jul 08, 2024 |
4 | Insider transactions | 1 | Jul 08, 2024 |
4 | Insider transactions | 1 | Jul 08, 2024 |
ars | Annual reports | 1 | Jun 14, 2024 |
def | Proxies and info statements | 5 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 07, 2024 |